載入...

Myeloablative reduced-toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life

The optimal pretransplant regimen for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients ≥55 years of age remains to be determined. The myeloablative reduced-toxicity 4-day regimen IV busulfan (Bu) (130 mg/m(2))-IV fludarabine (Flu) (40 mg/m(2)) is associated with low morbidi...

全面介紹

Na minha lista:

書目詳細資料
發表在:	Biol Blood Marrow Transplant
Main Authors:	Alatrash, Gheath, de Lima, Marcos, Hamerschlak, Nelson, Pelosini, Matteo, Wang, Xuemei, Xiao, Lianchun, Kerbauy, Fabio, Chiattone, Alexandre, Rondon, Gabriela, Qazilbash, Muzaffar H., Giralt, Sergio A., de Padua Silva, Leandro, Hosing, Chitra, Kebriaei, Partow, Zhang, Weiqing, Nieto, Yago, Saliba, Rima M., Champlin, Richard E., Andersson, Borje S.
格式:	Artigo
語言:	Inglês
出版:	2011
主題:	Article
在線閱讀:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4261630/ https://ncbi.nlm.nih.gov/pubmed/21338705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2011.02.007
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

Myeloablative reduced-toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life

相似書籍